Compare HCAT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | DERM |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 135.3M |
| IPO Year | 2019 | 2021 |
| Metric | HCAT | DERM |
|---|---|---|
| Price | $1.04 | $5.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $2.53 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 764.1K | 311.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | $61,858,000.00 |
| Revenue This Year | N/A | $47.42 |
| Revenue Next Year | N/A | $55.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.48 | ★ 10.20 |
| 52 Week Low | $1.04 | $4.31 |
| 52 Week High | $5.06 | $9.56 |
| Indicator | HCAT | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 36.68 |
| Support Level | N/A | $4.31 |
| Resistance Level | $2.41 | $7.92 |
| Average True Range (ATR) | 0.10 | 0.45 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 0.00 | 34.31 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.